|

Azer-cel Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Allogeneic Anti-CD19 CAR T cells, PBCAR0191

Pipeline

Phase 1: 1

Top Sponsors

  • Imugene Limited1

Indications

  • B-cell Acute Lymphoblastic Leukemia1
  • Small Lymphocytic Lymphoma1
  • Chronic Lymphocytic Leukemia1
  • Non-hodgkin Lymphoma1
  • Cancer1

Gilbert, Arizona1 trial

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

Banner MD Anderson Cancer Center

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.